New drug duo takes on deadly brain infection
NCT ID NCT07350174
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new two-drug combination (Alpibectir and Ethionamide) added to standard treatment for tuberculosis meningitis, a serious brain infection. About 64 adults newly diagnosed with the condition will receive the drugs to see how well they reach the brain and how safe they are. The trial also checks how the drugs interact with HIV treatment in patients who are HIV-positive.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS MENINGITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.